home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Arwan Pharmaceutical Industries, Lebanon

SHARESHARESHARE
Arwan Pharmaceutical Industries,are one of the most advanced biotech manufacturing facilities in the MENA and Africa. Our ultimate goal is to secure quality critical care medicine to all patients who need them. Thus, quality is embedded in each and every step of our operations, from the buildings, machineries, materials, methods and manpower. Empowered by our passion for achievement, strong belief in our capabilities, and the emphasis on performance with integrity, we continue to work according to our motto:
SHARESHARESHARE

RELATED NEWS


A blood test for a faulty protein may be able to predict more quickly and more accurately when bladder cancer is likely to return than existing methods, suggests a study* published in the British Journal of Cancer. It offers the tantalising prospect of being able to treat the disease at an earlier stage. Researchers from the University Hospital of Lyon analysed the urine samples of 348 patients previously treated for urothelial bladder cancer for a faulty protein called TERT, short for telomeras...

READ MORE

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is manufactured by Japanese firm Kyowa Hakko Kirin (Kyowa Kirin) and is for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. Poteligeo is a humanized monoclonal antibody, which acts against the against CC chemokine receptor 4 (CCR4), which is often found in the cells of patients with ce...

READ MORE

Alexion Pharmaceuticals is a company focused on ultra-rare diseases, although it is working on a shift into rare diseases. This may sound like something of a minor shift, but it represents developing drugs for more diseases with larger patient populations. The company’s success has been built primarily on its Soliris (eculizumab), a complement inhibitor. The drug has been approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS) and for generalized M...

READ MORE

The white-hot biotech hub of Kendall Square just got a little bit more crowded. Ireland-based Allergan plc announced this morning that the company will establish an R&D facility in the Cambridge, Mass. neighborhood. David Nicholson, head of R&D for the company, said the decision to place a research and development facility in Kendall Square, a BioSpace HotBed region known as Genetown, was an easy decision. In a statement about the new facility, Nicholson noted that many of the driving so...

READ MORE

OHSU scientists have discovered a naturally occurring disease in monkeys that mimics a deadly childhood neurodegenerative disorder in people a finding that holds promise for developing new gene therapies to treat Batten disease. A multidisciplinary team of veterinarians and scientists at the Oregon National Primate Research Center made the discovery and confirmed through genetic analysis that a small population of Japanese macaque monkeys carry a mutation in the CLN7 gene that causes one form of...
OREGON HEALTH & SCIENCE UNIVERSITY
READ MORE

AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But heres something that could ease the pain- New outcomes data showing Farxiga cut cardiovascular risks in heart failure patients with or without diabetes. In a phase 3 trial, Farxiga cut the risk of cardiovascular death or hospitalization in patients with reduced ejection fraction HFrEF, when added to standard treatments for heart failure. The data could help Farxiga score a CV risk-...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...